肯尼斯·彼得斯博士表示，「我熱衷於探究」藥物濫用後綜合症
2025年5月20日
親愛的朋友們：
如果您曾經抱怨過 PFS 研究不夠，那麼您會很高興地得知，醫學博士 Kenneth M. Peters 不僅同意這一觀點，而且還致力於糾正這種流行病學上的不公正。
“In my practice, I’m seeing an increasing number of patients suffering long-term consequences from medications they’ve previously used. These include finasteride, Accutane, and SSRIs like Prozac, Zoloft and Celexa,” the Chair of Urology at Oakland University William Beaumont School of Medicine (OUWB) tells us.
“Very little is known about how these drugs can produce such devastating effects, nor do we know how they can be resolved,” he adds.
“There’s a tremendous need for research into, and awareness of, these post-drug syndromes. I’m passionate about getting to the bottom of them.”
Phase I in Dr. Peters’ project is a study titled, Interconnected Post-Drug Syndromes: Investigating the Impact of Retinoids, SSRIs, and Finasteride on Health and Well-being.
That research is one and the same with an anonymous, HIPAA-compliant survey designed to better gauge the severity of the most common post-drug syndromes (PDS).
“Additionally, our goal is to increase awareness about post-drug syndromes and engage the medical community to work together to identify potential therapies,” says Dr. Peters, adding that he will seek to publish his findings in a peer-reviewed journal.
Details of Phase II of the project is under wraps at the moment. But we can tell you that it will involve not only formulating more—and more in-depth—studies, but identifying funding sources for those projects.
“Additionally, our goal is to increase awareness about post-drug syndromes and engage the medical community to work together to identify potential therapies,” says Dr. Peters, adding that he will seek to publish his findings in a peer-reviewed journal.
Details of Phase II of the project is under wraps at the moment. But we can tell you that it will involve not only formulating more—and more in-depth—studies, but identifying funding sources for those projects.
Meanwhile, we encourage all PFS patients to participate in the survey, and all health care providers to recommend that their PDS patients do the same.
Anyone 18 years of age or older who took, then discontinued, finasteride, Saw Palmetto, retinoids, SSRIs, SNRIs or TCAs can complete the survey, which takes about 30 minutes.
Please be aware, however, that the deadline for participation is June 30.
To begin the process, click here.
Finasteride最初由默克公司（Merck & Co., Inc.）开发，并于1993 年首次获得美国食品药品监督管理局批准，作为保列治（5毫克，用于治疗前列腺增生），并于1997年再度获得批准，作为保法止（1毫克，用于脱发）。
2021年6月，默克将其子公司Organon剥离为一家独立的上市公司（NYSE：OGN）。Organon 成立于1923年的荷兰，致力于为女性、她们的家庭和她们所关心的社区带来世界级的医疗服务。
在交易中，Organon获得了默克的保列治和保法止等产品。如需报告任何菲娜雄安产品的副作用，请拨打Organon服务中心电话(844)674-3200，或发送电子邮件至Service_Center@Organon.com。
在美国的PFS患者应向美国FDA报告其症状。在美国以外的PFS患者应向美国FDA及其当地药品监管机构报告症状，具体信息请访问描述对你的副作用页面。
如果您或您的亲人正在遭受PFS，并感到抑郁或不稳定，请立即通过我们的患者支持热线联系PFS基金会：social@pfsfoundation.org。
谢谢。